Perspective: repurposed drugs for COVID-19

INTRODUCTION: The article aims to emphasize the necessity of proper research design, both scientifically and ethically, in order to provide good evidence for physicians to base their decisions on when prescribing drug treatment. METHODS: Research articles and guidelines related to therapy of COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Na-Bangchang, Kesara, Porasuphatana, Supatra, Karbwang, Juntra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479713/
https://www.ncbi.nlm.nih.gov/pubmed/36160358
http://dx.doi.org/10.5114/aoms/152467
Descripción
Sumario:INTRODUCTION: The article aims to emphasize the necessity of proper research design, both scientifically and ethically, in order to provide good evidence for physicians to base their decisions on when prescribing drug treatment. METHODS: Research articles and guidelines related to therapy of COVID-19 were searched from the PubMed database. RESULTS: Only remdesivir and tocilizumab are medicines that have been approved by the US FDA’s decision to approve their clinical use in moderate and severe COVID-19. CONCLUSIONS: Favipiravir, ivermectin and andrographolide need further well-conducted research to confirm the efficacy and safety against COVID-19 at different stages.

Ejemplares similares